Implant Helps Patient with Neurodegenerative Disease to Walk Again
A woman bedridden for over a year due to a debilitating neurodegenerative disease was able to get up and walk again, thanks to an innovative electrical stimulation system which was able to raise her blood pressure on standing and prevent her fainting. The system was developed by a team headed by Professors Jocelyne Bloch and Grégoire Courtine, and was detailed in The New England Journal of Medicine.
Their system includes electronics implanted directly on the spinal cord to reactivate the neurons that regulate blood pressure, thereby preventing the patient from losing consciousness every time she’s in an upright position. This type of implant was already in use for the treatment of low blood pressure in tetraplegic patients.
The female patient in the study suffers from multiple system atrophy-parkinsonian type (MSA-P), a neurodegenerative disease that afflicts several parts of the nervous system, including the sympathetic nervous system.
MSA-P leads to the loss of sympathetic neurons regulating blood pressure, which results in orthostatic hypotension, a dramatic blood pressure drop when patients are in an upright position, which in some cases results in fainting. This increases fall risks, limits mobility, and can eventually shorten life expectancy. Having to remain in a reclined position to avoid passing out severely impacts patients’ quality of life.
The implant consists of a set of electrodes connected to an electrical-impulse generator typically used to treat chronic pain. After implanting their device directly on the patient’s spinal cord, the researchers found an improvement in the body’s capacity to regulate blood pressure, enabling the patient to remain conscious for longer periods in an upright position and to begin physical therapy to walk again. After being bedridden for 18 months, the patient is now able to walk as far as 250 metres.
For Jocelyne Bloch, this marks an important step toward the treatment of degenerative diseases: “We’ve already seen how this type of therapy can be applied to patients with a spinal-cord injury. But now, we can explore applications in treating deficiencies resulting from neurodegeneration. This is the first time we’ve been able to improve blood-pressure regulation in people suffering from MSA.”
Grégoire Courtine added that “this technology was initially intended for pain relief, not for this kind of application. Going forward, we and our company Onward Medical plan to develop a system targeted specifically to orthostatic hypotension that can help people around the world struggling with this disorder.”